Supported by our 650 employees we develop and manufacture
active pharmaceutical ingredients and pharmaceuticals to the highest international standards.

Since 2008, we have been a subsidiary of
FAREVA Group, which operates in 13 countries and has 41 production sites and 16 research and development centers around the world.


Our key focus is on developing and manufacturing products for cancer treatment and immunosuppressive therapies.